In this month's journal scan, our panel reviews:
Homologous recombination repair mutation gene panels (excluding BRCA) are not predictive of maintenance olaparib plus bevacizumab efficacy in the first-line PAOLA-1/ENGOT-ov25 trial
Pujade-Lauraine E. Presented at: 2021 Society of Gynecologic Oncology Annual Meeting. March 19-25. Virtual.
Irman Forghani, MD
Maintenance olaparib for patients with newly diagnosed, advanced ovarian cancer and a BRCA mutation: 5-year follow-up from SOLO1
W. Bradley, 2021. Society of Gynecologic Oncology Virtual Meeting, March 2021.
Dana Chase, MD, FACOG
Randomized Phase II Placebo-Controlled Trial with Farletuzumab (FAR) or Placebo Plus Carboplatin/Paclitaxel or Carboplatin/Pegylated Liposomal Doxorubicin in Low CA-125 Platinum-Sensitive Ovarian Cancer
Herzog TJ. SGO Annual Meeting, Oral Scientific Plenary, 2021.
Thomas J. Herzog, MD
Efficacy of niraparib by timing of surgery and residual disease: a post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study
O’Cearbhaill R, Pérez-Fidalgo J-A, Monk BJ, et al. Poster presented at: Society of Gynecologic Oncology 2021 Virtual Annual Meeting, March 19-25, 2021. Poster 10381.
Brian Slomovitz, MD